Trillium Therapeutics Inc. announced the closing of its previously announced transaction with Pfizer Inc. and PF Argentum Acquisition ULC (Purchaser), pursuant to the previously announced arrangement agreement dated August 20, 2021 by and among Trillium, Pfizer and Purchaser. In connection with the completion of the Arrangement and following the Effective Time, Jan Skvarka (President and Principal Executive Officer), Robert Uger (Chief Scientific Officer), Ingmar Bruns (Chief Medical Officer), James Parsons (Principal Financial Officer and Principal Accounting Officer) and Penka Petrova (Chief Development Officer and Principal Operating Officer) ceased to serve in their capacities as executive officers of Trillium. Following the Effective Time, Deborah Baron will serve as President. Also, effective as of the Effective Time, each then-member of the board of directors of Trillium, consisting of Jan Skvarka, Luke Beshar, Michael Kamarck, Catherine Mackey, Helen Tayton-Marton, Scott Myers, Paolo Pucci, and Paul Walker, resigned from the Trillium board of directors and all committees thereof. Effective immediately following these resignations, Deborah Baron and Andrew Muratore became the directors of Trillium.